COSTA MESA, California - 15 August 2004 - In the July 2004 issue of The Ocular Surface, world-renown ophthalmologist, Dr. Thomas John, co-authored “Amniotic Membrane Transplantation in the Management of Severe Ocular Surface Disease: Indications and Outcomes”.
In this review, Drs. John and Bouchard assess the indications and outcomes of amniotic membrane transplantation (AMT) based on 661 cases. The paper uniquely details the pluri-indicational, surgical use of AMT for conjunctival, corneal and tectonic conditions. |
E.Ziegler with amnion-expert, Dr. Thomas John,
M.D. at 2003 ARVO meeting |
The article summarizes the important resource AMT offers ophthalmic surgeons in the management of patients with severe ocular surface disease.
Thomas John, MD is a Clinical Associate Professor at Loyola University at Chicago in Maywood, Illinois, and has offices in Tinley Park and Oak Lawn, Illinois, and in Merrillville, Indiana. Dr. John is recognized as an industry leader in AMT use, research and technology innovation.
“Dr. John’s data in this review is the most comprehensive and detailed to-date pertaining to the surgical use of AMT”, comments Erich Ziegler, Vice President. “This information now allows us to succinctly and accurately detail eye professionals on the uses and outcomes of amnion for eye surgery.”
AmbioDry Allografts, dehydrated tissue grafts derived from human placenta, are employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. In comparison to competitive tissue options, the advantages of the AmbioDry are vast.
About IOP
Founded in 1988, IOP, Inc. develops and commercializes specialized, leading-edge surgical technologies for eye surgery. IOP's purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.
IOP currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for cornea, anterior and oculoplastic surgeries.
Media Contact:
media@iopinc.com
Back to Recent News
|
